fda compounding semaglutide warning letter news Democratic lawmakers are pressing the Trump administration to disclose who received special access to Eli Lilly's investigational obesity drug retatrutide. Sen. Maggie Hassan (D-N.H.) sent a to HHS Secretary Robert F FDA warns consumers not to

When discussing gastrointestinal side effects, including heartburn, with your prescriber, it is helpful to: Keep a symptom diary noting when symptoms occur, their severity, duration, and any potential triggers Report all concurrent medications and supplements , as some including non-steroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics can independently worsen reflux or interact with gastrointestinal function [8] [9] Ask about dose titration options if symptoms are significantly affecting your quality of life Discuss whether a formal GORD assessment is warranted , particularly if symptoms are persistent your GP may consider Helicobacter pylori testing or referral for endoscopy based on NICE CKS and NG12 criteria Your prescriber may refer you to a gastroenterologist if symptoms are complex or do not resolve with standard management

Avoid screens at least 1 hour before bed

Furthermore, GLP-1 RAs exhibit vasodilatory effects by promoting endothelial nitric oxide (NO) synthesis, enhancing endothelial function with a consequent reduction of vascular resistance and an improvement in cardiac afterload [45, 46]

It was only in the early 1990s that researchers first infused GLP-1 intravenously in a clinical trial

Gastroenterology 158 , 537549.e510 (2020)

contact a GP or trial team promptly for persistent vomiting, severe abdominal pain, or symptoms suggesting pancreatitis or gallbladder disease